Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor: NSABP Foundation Inc
Study ID: NCT00314353
Phase: PHASE2
Status: Terminated

Conditions

Colorectal Neoplasms

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Bevacizumab — DRUG
7.5 mg/kg IV Day 1 every 21 days for eight cycles\* \*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression.
Oxaliplatin — DRUG
130 mg/m2 IV Day 1 every 21 days for eight cycles
Capecitabine — DRUG
850 mg/m2 po BID Days 1-14 every 21 days for eight cycles\*# \*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression. #For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID
Irinotecan — DRUG
200 mg/m2 IV Day 1 every 21 days for eight cycles

Study Details

Bevacizumab is an angiogenesis inhibitor which means it works to stop blood vessel formation in tumors. Without new blood vessels, the growth of a tumor is slowed. Chemotherapy works to kill cancer cells directly. This study is being done to see how colorectal cancer responds to treatment with the combination of bevacizumab and chemotherapy.